Lung Cancer Edition: Top Headlines for Week of May 13, 2024
Manage episode 418412243 series 3560281
In this edition, smoking cessation support uptake at lung cancer screenings, glecirasib may deliver ‘efficacy and tolerability advantages’ and more. Read the full coverage here:
Uptake of smoking cessation support high when offered at lung cancer screening
Glecirasib may deliver ‘efficacy and tolerability advantages’ for KRAS-mutant lung cancer
‘Substantial geographic disparities’ worsening in cancer clinical trial availability
Deployed military personnel have increased silica in lung tissue
FDA approves Alecensa for certain patients with ALK-positive lung cancer
References:
Lowers H, et al. Int J Environ Res Public Health. 2024;doi:10.3390/ijerph21010091.Press Release
Murray RL, et al. Eur Respir J. 2024;doi:10.1183/13993003.01768-2023.
Sekar RR, et al. JAMA Netw Open. 2024;doi:10.1001/jamanetworkopen.2024.10162.
Shi Y, et al. Abstract 468214. Presented at: ASCO Plenary Series; April 30, 2024.
118 episoder